Discovery and validation of autosomal dominant Alzheimer's disease mutations

Simon Hsu  
*Washington University School of Medicine in St. Louis*

Brian A Gordon  
*Washington University School of Medicine in St. Louis*

Russ Hornbeck  
*Washington University School of Medicine in St. Louis*

Joanne B Norton  
*Washington University School of Medicine in St. Louis*

Denise Levitch  
*Washington University School of Medicine in St. Louis*

*See next page for additional authors*

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

**Recommended Citation**

Hsu, Simon; Gordon, Brian A; Hornbeck, Russ; Norton, Joanne B; Levitch, Denise; Louden, Adia; Ziegemeier, Ellen; Laforce, Robert; Chhatwal, Jasmeer; Day, Gregory S; McDade, Eric; Morris, John C; Fagan, Anne M; Benzinger, Tammie L S; Goate, Alison M; Cruchaga, Carlos; Bateman, Randall J; Dominantly Inherited Alzheimer Network (DIAN); and Karch, Celeste M, "Discovery and validation of autosomal dominant Alzheimer’s disease mutations.” Alzheimer's Research & Therapy. 10, 1. 67 (2018). https://digitalcommons.wustl.edu/open_access_pubs/8285
Authors
Discovery and validation of autosomal dominant Alzheimer’s disease mutations


Abstract

Background: Alzheimer’s disease (AD) is a neurodegenerative disease that is clinically characterized by progressive cognitive decline. Mutations in amyloid-β precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) are the pathogenic cause of autosomal dominant AD (ADAD). However, polymorphisms also exist within these genes.

Methods: In order to distinguish polymorphisms from pathogenic mutations, the DIAN Expanded Registry has implemented an algorithm for determining ADAD pathogenicity using available information from multiple domains, including genetic, bioinformatic, clinical, imaging, and biofluid measures and in vitro analyses.

Results: We propose that PSEN1 M84V, PSEN1 A396T, PSEN2 R284G, and APP T719N are likely pathogenic mutations, whereas PSEN1 c.379_382delXXXXinsG and PSEN2 L238F have uncertain pathogenicity.

Conclusions: In defining a subset of these variants as pathogenic, individuals from these families can now be enrolled in observational and clinical trials. This study outlines a critical approach for translating genetic data into meaningful clinical outcomes.

Keywords: APP, PSEN1, PSEN2, Autosomal dominant Alzheimer’s disease, Cell-based assays, Pathogenicity algorithm

Background

Alzheimer’s disease (AD) is characterized clinically by progressive cognitive decline and neuropathologically by progressive neuronal loss and the accumulation of amyloid plaques and neurofibrillary tangles. Mutations in amyloid-β precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) are the pathogenic cause of autosomal dominant AD (ADAD). More than 200 pathogenic mutations have been identified in APP, PSEN1, and PSEN2 (reviewed in [1, 2]). PSEN1 and PSEN2 form the catalytic domain of the γ-secretase complex, which is involved in sequential cleavage of APP into amyloid-β (Aβ) peptides.

The Dominantly Inherited Alzheimer Network (DIAN) is an observational study designed to follow families with mutations in APP, PSEN1, and PSEN2 that cause ADAD [3]. The DIAN Expanded Registry (DIAN EXR; www.dianexr.org) is a web-based registry with global outreach to ADAD families and investigators. It functions to identify families with ADAD and to determine the causative mutations through a genetic discovery program. This program includes genetic counseling and testing for known and unknown causes of ADAD. During a period of 6 years (2011 to 2017), the DIAN Clinical/Genetics committee reviewed 150 pedigrees, 76 of which were approved for genetic counseling and testing. Forty-six probands were positive for a coding variant in APP, PSEN1, or PSEN2, including 39 individuals with known pathogenic mutations, 6 with variants of unknown pathogenic significance, and 1 variant that was determined to be an AD risk factor.

In some cases, families are identified with several generations of early-onset AD; however, at the time of enrollment, whether a pathogenic mutation is the cause of disease in these families remains unknown. We performed genetic analyses in research participants from six densely
affected early-onset AD pedigrees and identified variants in APP, PSEN1, and PSEN2 with unknown pathogenicity. In all families examined, we lacked sufficient genetic material to perform segregation analyses (e.g., DNA was available from only one or two family members). To assess the pathogenicity of novel variants in APP, PSEN1, and PSEN2 when pedigree and clinical data are limited or incomplete, Guerreiro and colleagues [4] proposed a pathogenicity algorithm. In the present study, we modified and expanded this algorithm to evaluate the pathogenicity of these six variants using genetic, biochemical, biomarker, and clinical data.

### Methods

#### Genetic screening

Genomic DNA was extracted from peripheral blood lymphocytes using standard protocols. All coding exons in APP, PSEN1, and/or PSEN2 were amplified and sequenced using the BigDye Terminator version 3.1 cycling sequencing kit (Life Technologies, Carlsbad, CA, USA) and analyzed on an ABI 3500 genetic analyzer (Life Technologies). Sequence analysis was performed using Sequencer software (Gene Codes, Ann Arbor, MI, USA).

#### Bioinformatics

To determine whether APP, PSEN1, and PSEN2 variants represented rare or common polymorphisms, we investigated two population-based exome sequencing databases: the Exome Variant Server (EVS) and Exome Aggregation Consortium (ExAC) browser. Polymorphism phenotype (PolyPhen-2; [5]) and Sorting Intolerant From Tolerant (SIFT) were used to predict whether the amino acid change would be disruptive to the encoded protein.

#### Cerebrospinal fluid

Cerebrospinal fluid (CSF) was collected by lumbar puncture under fasting conditions from the PSEN1 M84V carrier and noncarrier. CSF Aβ42, total tau, and tau phosphorylated at threonine 181 (p-tau181) were measured by immunoassay (xMAP; Luminex, Austin, TX, USA) as previously described [6].

#### PiB imaging

Structural magnetic resonance imaging (MRI) was performed using 3-T scanners and following the Alzheimer's Disease Neuroimaging Initiative (ADNI) protocol [7, 8]. T1-weighted scans were processed through FreeSurfer. Positron emission tomography with Pittsburgh compound B (PiB) was coregistered with MRI images. The standardized uptake value ratio (SUVR) was calculated for each region [9, 10]. Global burden was characterized using a summary measure [9]. These data were collected for a PSEN1 M84V carrier and noncarrier.

### Biochemical analysis

#### Plasmids and mutagenesis

The full-length PSEN1 complementary DNA (cDNA) was cloned into pcDNA3.1 Myc/His vector [11]. The M84V, c.379_382delXXXinsG, or A396T variant was introduced into the PSEN1 cDNA using the QuickChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA). Clones were sequenced to confirm the presence of the variant and the absence of additional modifications. PSEN1 wild type (WT) and the pathogenic PSEN1 A79V mutation were included as controls.

The full-length PSEN2 cDNA was cloned into pcDNA3.1 vector [12]. The L238F or R284G variant was introduced into the PSEN2 cDNA and screened as described above. PSEN2 WT and the pathogenic PSEN2 N141I mutation were included as controls [13].

The full-length APP cDNA (isoform 695) was cloned into pcDNA3.1 [14]. The T719N variant was introduced into the APP cDNA and screened as described above. APP WT and the pathogenic APP KM670/671NL(Swe) mutation were included as controls.

#### Transient transfection

To assess novel PSEN1 and PSEN2 variants, we used neuroblastoma cells (N2A) stably expressing human APP WT (695 isoform; N2A695). To assess novel APP variants, we used N2A. N2A cells were maintained in equal amounts of DMEM and Opti-MEM, supplemented with 5% FBS, 2 mM L-glutamine, 100 μg/ml penicillin/streptomycin, and, for stable cells, 200 μg/ml G418 (Life Technologies). Upon reaching confluence, cells were transiently transfected with LipoFectamine 2000 reagent (Life Technologies). Culture media were replaced after 24 hours, and cells were incubated for another 24 hours prior to analysis. Four independent transfections were performed for each construct and used for subsequent analyses.

#### Aβ enzyme-linked immunosorbent assay

Conditioned medium was collected and centrifuged at 3000 x g at 4 °C for 10 minutes to remove cell debris. The levels of Aβ40 and Aβ42 were measured in cell culture media by sandwich enzyme-linked immunosorbent assay (ELISA) as described by the manufacturer (Life Technologies). To account for variability in transfection efficiency between experiments, ELISA values were obtained (pg/ml) and corrected for total intracellular protein (μg/ml). Statistical difference was measured using an unpaired Student’s t test.

### Results and discussion

#### PSEN1 M84V

The proband was identified in a family with three generations of early-onset AD and with a mean age at onset of 59 years (Fig. 1; pedigree not shown to avoid...
disclosing mutation status to asymptomatic proband and other family members). Sequencing of the proband revealed a single base substitution (ATG to GTG) at codon 84 in exon 4 of PSEN1, resulting in a methionine-to-valine change (M84V). PSEN1 M84V was also identified in a family-based sequencing study of AD (National Institute of Mental Health Alzheimer’s Disease Genetics Initiative Study) [15]. Two PSEN1 M84V carriers were confirmed to have had AD at autopsy with ages at symptomatic onset of 70 and 72 years. The third carrier was cognitively normal at age 67 years [15].

To determine whether PSEN1 M84V represents a rare polymorphism, we examined two population-based exome sequencing databases (Table 1). Two PSEN1 M84V carriers were confirmed to have had AD at autopsy with ages at symptomatic onset of 70 and 72 years. The third carrier was cognitively normal at age 67 years [15].

We next sought to determine whether the PSEN1 M84V variant alters Aβ isoform levels in a manner consistent with previously reported pathogenic PSEN1 mutations. We expressed vectors containing PSEN1 WT, A79V (a known pathogenic mutation), and M84V in N2A695 cells. We found that cells expressing PSEN1 M84V produced significantly more Aβ42 than cells expressing PSEN1 WT (Fig. 3a–c). We also observed a significant increase in the Aβ42/Aβ40 ratio in cells expressing PSEN1 M84V or the pathogenic PSEN1 A79V-compared with PSEN1 WT-expressing cells (Fig. 3c).

Thus, we can apply a pathogenicity algorithm, modified from Guerreiro and colleagues [4], to assess the pathogenicity of PSEN1 M84V (Fig. 4). PSEN1 M84V occurs within exon 4 and the first transmembrane domain. This residue is highly conserved between PSEN1 and PSEN2 [16]. Additionally, a pathogenic mutation has been reported at this site: ΔI83/M84 [17, 18]. In a cell model, Aβ levels were consistent with pathogenic mutations (Fig. 3a–c, g). Thus, PSEN1 M84V satisfies all criteria for pathogenicity based on residue and Aβ levels [4]. Taken together, we propose that PSEN1 M84V represents a pathogenic mutation.

**PSEN1 A396T**

The proband was identified in a family with three generations of early-onset AD (Fig. 1a). The proband had an age at symptomatic onset of 50 years. The parent of the proband had an age at symptomatic onset of 57 years, with AD confirmed at autopsy at age 67 years. Sequencing of the proband (Fig. 1a) revealed a single base substitution (GCC to ACG) at codon 396 in exon 11 of PSEN1, resulting in an alanine-to-threonine change (A396T). This variant was reported previously in one individual with sporadic AD [19]. PSEN1 A396T was absent in the EVS and ExAC databases (Table 1). We found that cells expressing PSEN1 A396T produced significantly more Aβ42 than cells expressing PSEN1 WT (Fig. 3a–c). Thus, applying the algorithm for assessing pathogenicity (Fig. 4), we propose that the PSEN1 A396T represents a probable pathogenic mutation.

**PSEN1 c.379_382delXXXXinsG**

The proband had an age at symptomatic onset of 50 years, with an average age at symptomatic onset in family members aged 43 years (Fig. 1b). Sequencing of
Table 1 Bioinformatic analysis of APP, PSEN1, and PSEN2 variants of unknown pathogenicity

<table>
<thead>
<tr>
<th>Gene</th>
<th>Variant</th>
<th>EVS a</th>
<th>ExAC b</th>
<th>PolyPhen</th>
<th>SIFT</th>
<th>Variant previously reported</th>
<th>Location</th>
<th>PSEN1-PSEN2 conservation</th>
</tr>
</thead>
<tbody>
<tr>
<td>APP</td>
<td>T719N</td>
<td>0</td>
<td>0</td>
<td>Probably damaging</td>
<td>Damaging</td>
<td>Yes</td>
<td>Exon 17</td>
<td>N/A</td>
</tr>
<tr>
<td>PSEN1</td>
<td>M84V</td>
<td>0</td>
<td>0</td>
<td>Probably damaging</td>
<td>Tolerated</td>
<td>Yes</td>
<td>Exon 4 (TM-1)</td>
<td>Yes</td>
</tr>
<tr>
<td>PSEN1</td>
<td>c.379_382delXXXXinsG</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
<td>Tolerated</td>
<td>No</td>
<td>Exon 5 (HL1)</td>
<td>Yes</td>
</tr>
<tr>
<td>PSEN1</td>
<td>A396T</td>
<td>0</td>
<td>0</td>
<td>Probably damaging</td>
<td>Tolerated</td>
<td>Yes</td>
<td>Exon 11 (HL8)</td>
<td>No</td>
</tr>
<tr>
<td>PSEN2</td>
<td>L238F</td>
<td>2</td>
<td>2</td>
<td>Probably damaging</td>
<td>Damaging</td>
<td>Yes</td>
<td>Exon 7 (TM-V)</td>
<td>Yes</td>
</tr>
<tr>
<td>PSEN2</td>
<td>R284G</td>
<td>0</td>
<td>0</td>
<td>Probably damaging</td>
<td>Damaging</td>
<td>No</td>
<td>Exon 8</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Abbreviations: PolyPhen Polymorphism phenotype, SIFT Sorting Intolerant From Tolerant, EVS Exome Variant Server, ExAC Exome Aggregation Consortium, PSEN Presenilin, APP Amyloid precursor protein

aRepresents sequence data from 4300 unrelated European Americans (8598 alleles)
bRepresents sequence data from 60,706 unrelated European Americans (121,204 alleles)

Fig. 2 Pittsburgh compound B (PiB) uptake in the brain of a presymptomatic PSEN1 M84V carrier is consistent with presymptomatic autosomal dominant Alzheimer's disease mutation carriers. 11C-PiB positron emission tomographic scans were performed longitudinally in a PSEN1 M84V noncarrier and carrier. The color scale for standardized uptake values (SUV) indicate red (high), yellow (medium), and blue (low) PiB retention. EYO Estimated years of onset.
the proband (Fig. 1b) revealed a 4-bp deletion and insertion of G at codon 127 in exon 5 of PSEN1, resulting in the deletion of glutamine and arginine and insertion of glycine (c.379_382delXXXXinsG). This is a novel variant and was absent from the EVS and ExAC databases (Table 1). N2A695 expressing PSEN1 c.379_382delXXXXInsG produced Aβ42 and Aβ40 levels similar to PSEN1 WT (Fig. 3a–c). Thus, we propose that PSEN1 c.379_382delXXXXInsG is an AD risk factor or benign polymorphism.

**PSEN2 R284G**

The proband had an age at symptomatic onset of 58 years, with average age at symptomatic onset in the family of 56 years (Fig. 1c). Sequencing of the proband (Fig. 1c) revealed a single base pair substitution (CGG to GGG) at codon 284 in exon 8 of PSEN2, resulting in an arginine-to-glycine change (R284G). This is a novel variant and was absent from the EVS and ExAC databases (Table 1).

To assess the effects of PSEN2 variants on Aβ isoform levels, we expressed vectors containing PSEN2 WT, N141I, and R284G in N2A695 cells. Cells expressing PSEN2 N141I and R284G in N2A695 cells. Cells expressing PSEN2 N141I and R284G produced significantly more Aβ42 than cells expressing PSEN2 WT (Fig. 3d and e). The Aβ42/Aβ40 ratio was also significantly higher in cells expressing PSEN2 N141I and R284G (Fig. 3f). Thus, applying the algorithm for assessing pathogenicity (Fig. 4), we propose that the PSEN2 R284G represents a probable pathogenic mutation.
The proband was identified in a family with three generations of early-onset AD (Fig. 1d). The proband had an age at symptomatic onset of 49. The parent of the proband was diagnosed with AD at 57 years of age and died at age 77. Sequencing of the proband (Fig. 1d) revealed a single base pair substitution (CTT to TTT) at codon 238 in exon 7 of PSEN2, resulting in a leucine-to-phenylalanine change (L238F). PSEN2 L238F was also identified in two alleles in EVS, in two alleles in ExAC, and in one individual with sporadic AD (Table 1; [20]). Cells expressing PSEN2 L238F produced Aβ42 and Aβ40 levels similar to PSEN2 WT (Fig. 3d–f). Thus, we propose that PSEN2 L238F represents an AD risk factor or benign polymorphism.

**PSEN2 L238F**

The proband was identified in a family with three generations of early-onset AD (Fig. 1d). The proband had an age at symptomatic onset of 49. The parent of the proband was diagnosed with AD at 57 years of age and died at age 77. Sequencing of the proband (Fig. 1d) revealed a single base pair substitution (CTT to TTT) at codon 238 in exon 7 of PSEN2, resulting in a leucine-to-phenylalanine change (L238F). PSEN2 L238F was also identified in two alleles in EVS, in two alleles in ExAC, and in one individual with sporadic AD (Table 1; [20]). CSF Aβ, total tau, and phosphorylated tau were measured in a PSEN2 L238F carrier related to the proband, who was cognitively normal at the time of lumbar puncture. CSF Aβ (506.54 pg/ml), total tau (38.75 pg/ml), and p-tau181 (21.33 pg/ml) at 17 years prior to the parental age at symptomatic onset was consistent with biomarker levels in normal controls [3, 6]. Cells expressing PSEN2 L238F produced Aβ42 and Aβ40 levels similar to PSEN2 WT (Fig. 3d–f). Thus, we propose that PSEN2 L238F represents an AD risk factor or benign polymorphism.

**APP T719N**

The proband was identified in a family with two generations of early-onset AD (Fig. 1e). The proband had an age at symptomatic onset of 45 years. The parent of the proband was diagnosed at 45 years of age. Sequencing of the proband (Fig. 1e) revealed a single base pair substitution (ACC to AAC) at codon 719 in exon 17 of APP, resulting in a threonine-to-asparagine change (T719N). APP T719N was absent in the EVS and ExAC databases and was detected in one individual with early-onset AD (Table 1; [21]). Cells expressing APP T719N produced significantly elevated levels of Aβ42 and Aβ42/Aβ40 relative to APP WT (Fig. 3g–i). Thus, we propose that APP T719N is a probable pathogenic mutation.

**Conclusions**

By applying genetic, bioinformatic, and functional data to an algorithm to assess pathogenicity, we propose that the PSEN1 M84V, PSEN1 A396T, PSEN2 R284G, and APP T719N are likely pathogenic mutations resulting in ADAD, whereas PSEN1 c.379_382delXXXXInsG
PSEN2 L238F are likely benign polymorphisms. This algorithm was adapted and modified from a pathogenicity algorithm originally proposed by Guerreiro and colleagues [4]. We have expanded upon this algorithm in several important ways: (1) expanding the number of controls in the association analyses from 100 to 65,000 by exploiting the EVS and ExAC databases; (2) evaluating the bioinformatic functional findings (e.g., conservation between PSEN1 and PSEN2 and the presence of other mutations at the same residue) independent of the cell-based functional findings; and (3) incorporating cell-based assays to evaluate the impact of novel variants on Aβ levels. We propose that this modified approach to assessing pathogenicity provides an important pipeline for incorporating mutation data at several levels and that this algorithm may be adapted to impute pathogenicity when extensive genetic data are missing for affected families. Designation of a variant as pathogenic will allow individuals to enroll in observational and clinical trials for AD, with clear applications in clinical and research settings.

Acknowledgements
We gratefully acknowledge the altruism of the participants and their families and contributions of the DIAN research and support staff at each of the participating sites for their contributions to this study. The DIAN Expanded Registry welcomes contact from any families or treating clinicians interested in research about autosomal dominant familial Alzheimer’s disease. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders and the departments of neurology and psychiatry at Washington University School of Medicine. This article was reviewed by DIAN Study investigators for scientific content and consistency of data interpretation with previous DIAN study publications. We acknowledge the altruism of the participants and their families and the contributions of the DIAN research and support staff at each of the participating sites for their contributions to this study. We thank the DIAN Steering Committee: Ricardo Allegr, Tammie Benzinger, Sarah Berman, Virginia Buckles, Nigel Cairns, Helena Chui, Maritsa Ciberto, Anne Fagan, Howard Feldman, Bernardino Ghetti, Neill Graff-Radford, David Holtzman, Rachel Huber, Mathias Jucker, Jae-Hong Lee, Johannes Levin, Daniel Marcus, Ralph Martins, Colin Masters, Hiroshi Mori, James Noble, Nick Fox, Stephen Salloway, Peter Schofield, Michael Weinier, and Chengjie Xiong.

Funding
Funding provided by the DIAN Expanded Registry (to RJB), National Institutes of Health grant K01 AG046574 (to CMK) and DIAN-TU Pharma Consortium (https://dian.wustl.edu/our-research/the-pharma-consortium/), to RJB, CC, AMG, CWK; Fidelity Biosciences Research Initiative (RJB, CC, and CWK), and the Gerald and Henrietta Rauenhorst Foundation (RJB, CC, and CMK). Data collection and sharing for this project were supported by The Dominantly Inherited Alzheimer’s Network (DIAN; grant U1FAG032438) funded by the National Institute on Aging (NIA), the German Center for Neurodegenerative Diseases (DZNE), and the Institute for Neurological Research Dr. Raul Carrea (FLENI). Partial support was received through research and development grants for dementia from the Japan Agency for Medical Research and Development (AMED) and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI). The funding bodies played no role in the design of the study; in the collection, analysis, and interpretation of data; or in the writing of the manuscript.

Authors’ contributions
SH and CMK wrote the manuscript. CMK designed cell culture studies. SH, AL, and CMK performed cell culture experiments. JBN, DI, EZ, RL, GSD, EM, JC, JCW, and RJB recruited participants. BAG, RH, and TSLB performed and analyzed brain imaging. AMF analyzed CSF biomarker data. EZ, GSD, EM, AMG, CC, and RJB reviewed pedigrees. CMK performed bioinformatic analysis. All authors contributed to critical revision of the manuscript for intellectual content, and all authors read and approved the final manuscript.

Ethics approval and consent to participate
The Washington University Institutional Review Board reviewed the study protocol (IRB no. 201111194). All subjects included in this study, or their proxies, gave written informed consent.

Competing interests
AMG is a member of the scientific advisory board for Denali Therapeutics and serves on a genetic scientific advisory panel for Pfizer. RJB receives laboratory research funding from the National Institutes of Health, the Alzheimer’s Association, the BrightFocus Foundation, the Rainwater Foundation Tau Consortium, the Association for Frontotemporal Degeneration, the Cure Alzheimer’s Fund, and the tau SILK Consortium (AbbVie, Biogen, and Eli Lilly and Co.). Funding for clinical trials not related to this research include the National Institutes of Health, the Alzheimer’s Association, Eli Lilly and Co., Hoffman La-Roche, Janssen, Avid Radiopharma-ceuticals, the GHR Foundation, and an anonymous foundation. RJB also receives research funding from the DIAN Pharma Consortium (AbbVie, Amgen, AstraZeneca, Biogen, Eisai, Eli Lilly and Co., Hoffman La-Roche, Janssen, Pfizer, and Sanofi). RJB has received honoraria from Janssen and Pfizer as a speaker and from Merck and Pfizer as an advisory board member. Washington University, RJB, and DMH have equity ownership interest in C2N Diagnostics and receive royalty income based on technology (stable isotope labeling kinetics and blood plasma assay) licensed by Washington University to C2N Diagnostics. RJB receives income from C2N Diagnostics for serving on the scientific advisory board. Washington University, with RJB as coinventor, has submitted the U.S. nonprovisional patent application “Methods for measuring the metabolism of CNS derived biomolecules in vivo” and the provisional patent application “Plasma based methods for detecting CNS amyloid deposition.” The remaining authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Psychiatry, Washington University School of Medicine, 425 S. Euclid Ave, Campus Box 8134, St. Louis, MO 63110, USA. 2Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA. 3Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA. 4Clinique Interdisciplinaire de Mémoire du CHU de Québec, Département des Sciences Neurologiques, Faculté de Médecine, Université Laval, Québec City, Québec, Canada. 5Massachusetts General Hospital/ Martinos Center for Biomedical Imaging, 149 13th Street, Gerontology Research Room 2669, Charlestown, MA 02129, USA. 6Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA. 7Department of Neurosciences, Mount Sinai School of Medicine, New York, NY, USA.

Received: 6 February 2018 Accepted: 30 May 2018

Published online: 18 July 2018

References


